Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing

European Journal of Neuroscience

Volumn 15, Issue 7, 2002, Pages 1187-1196

  Marchese, Giorgio ^a   Casu, Maria Antonietta ^a   Bartholini, Francesco ^a   Ruiu, Stefania ^a   Saba, Pierluigi ^c   Gessa, Gian Luigi ^a,b,c   Pani, Luca ^a,b  

^a Neuroscienze PharmaNess Scarl   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Neurotoxicity; Parkinson; Tardive dyskinesia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CELL STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MALE; MASTICATION; NERVE CELL; NONHUMAN; NUCLEUS ACCUMBENS; PERIKARYON; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; SUBSTANTIA NIGRA; TEGMENTUM; TIME; WITHDRAWAL SYNDROME;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; MASTICATION; NEOSTRIATUM; NERVE DEGENERATION; NEURAL PATHWAYS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANTIA NIGRA; SULPIRIDE;

EID: 0036457014     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2002.01944.x     Document Type: Article

References (60)

1. Allard, P., Eriksson, K., Ross, S.B. & Marcusson, J.O. (1990) Unaltered [3H]-GBR-12935 binding after chronic treatment with dopamine active drugs. Psychopharmacology (Berl.), 102, 291-294.
2. Andreassen, O.A., Ferrante, R.J., Beal, M.F. & Jorgensen, H.A. (1998) Oral dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience, 87, 639-648.
3. Ase, A.R., Amdiss, F., Hebert, C., Huang, N., van Gelder, N.M. & Reader, T.A. (1999) Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J. Neural. Transm., 106, 75-105.
4. Bjorklund, L. & Stromberg, I. (1997) Dopaminergic innervation of striatal grafts placed into different sites of normal striatum: Differences in the tyrosine hydroxylase immunoreactive growth pattern. Exp. Brain Res., 113, 13-23.
5. Bloomquist, J., King, E., Wright, A., Mytilineou, C., Kimura, K., Castagnoli & K.Castagnoli, N. Jr (1994) 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: Cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther., 270, 822-830.
6. Burt, D.R., Creese, I. & Snyder, S.H. (1977) Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science, 196, 326-328.
7. Cadet, J.L. (1988) Free radical mechanism in the central nervous system: An overview. Int. J. Neurosci., 40, 13-18.
8. Casey, D.E. (1995) Tardive dyskinesya: Pathophysiology. In Bloom FE, Kupfer DJ, (eds) Psychopharmacology: The Fourth Generation of Progress, Raven, New York, pp. 1497-1502.
9. Ciliax, B.J., Heilman, C., Demchyshyn, L.L., Pristupa, Z.B., Ince, E., Hersch, S.M., Niznik, H.B. & Levey, A.I. (1995) The dopamine transporter: Immunochemical characterization and localization in brain. J. Neurosci., 15, 1714-1723.
10. Cochiolo, J.A., Ehsanian, R. & Bruck, D.K. (2000) Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: Evidence of compensatory plasticity in nigrostriatal neurons. J. Neurosci. Res., 59, 126-135.
11. Cotè, S.L., Ribeiro-da-Silva, A. & Cuello, A.C. (1993) Current protocols for light microscopy immunocytochemistry. In Cuello AC (ed). Immuno-histochemistry II, John Wiley, West Sussex, pp. 147-168.
12. Cottingham, S.L., Pickar, D., Shimotake, T.K., Montpied, P., Paul, S.M. & Crawley, J.N. (1990) Tyrosine hydroxylase and cholecystochinin mRNA levels in the substantia nigra, ventral tegmental area, and locus coeruleus are unaffected by acute and chronic haloperidol administration. Cell. Mol. Neurobiol., 10, 41-50.
13. De Keyser, J. (1991) Excytotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin. Neuropharmacol., 4, 562-565.
14. De Souza, I.E., McBean, G.J. & Meredith, G.E. (1999) Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur. J. Pharmacol., 382, 139-142.
15. Diana, M., Collu, M., Mura, A. & Gessa, G.L. (1992) Haloperidol-induced vacuous chewing in rats: Suppression by alpha-methyl-tyrosine. Eur. J. Pharmacol., 211, 415-419.
16. Egan, M.F., Hurd, Y., Ferguson, J., Bachus, S.E., Hamid, E.H. & Hyde, T.M. (1996) Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl), 127, 337-345.
17. Ellison, G. & See, R.E. (1989) Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacology (Berl), 98, 564-566.
18. Fang, J., Zuo, D. & Yu, P.H. (1995a) Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology (Berl), 121, 373-378.
19. Fang, J. & Yu, P.H. (1995b) Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices. Psychopharmacology (Berl), 121, 379-384.
20. Fibiger, H.C. & Lloyd, K.G. (1984) Neurobiological substrates of tardive dyskinesia: The GABA hypothesis. Trends Neurosci., 7, 462-464.
21. Gale, K. (1980) Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature, 283, 569-570.
22. Gunne, L.M., Andersson, U., Bondesson, U. & Johansson, P. (1986) Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol. Biochem. Behav., 25, 897-901.
23. Gunne, L.M., Growdon, J. & Glaeser, B. (1982) Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology (Berl), 77, 134-139.
24. Gunne, L.M., Haggstrom, J.E. & Sjoquist, B. (1984) Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature, 309, 347-349.
25. 3H] Raclopride binding to neostriatal homogenates. J. Pharmacol. Exp. Ther., 280, 268-276.
26. Hung, H.C. & Lee, E.H. (1998) MPTP produces differential oxidative stress and antioxidative respiration in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radic. Biol. Med., 24, 76-84.
27. Ikeda, H., Adachi, K., Hasegawa, M., Sato, M., Hirose, N., Koshikawa, N. & Cools, A.R. (1999) Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: Evaluation of a revised animal model of tardive dyskinesia. J. Neural. Transm., 106, 1205-1216.
28. Jeste, D.V. & Wyatt, R.J. (1979) In search of a treatment for tardive dyskinesia: Review of the letterature. Skizphr. Bull., 5, 251-292.
29. Jicha, G.A. & Salamone, J.D. (1991) Vacuous jaw movements and feeling deficits in rats with ventrolateral striatal dopamine depletion: Possible relation to parkinsonian symptoms. J. Neurosci., 11, 3822-3829.
30. Kelley, J.J., Gao, X.M., Tamminga, C.A. & Roberts, R.C. (1997) The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. Exp. Neurol., 146, 471-478.
31. Kelly, P.H., Seviour, P.W. & Iversen, S.D. (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septum and corpus striatum. Brain Res., 94, 507-522.
32. Klawans, H.L., D'amico, D.J., Nausieda, P.A. & Weiner, W.L. (1977) The specificity of neuroleptic- and methysergide-induced behavioural hypersensitivity. Psychopharmacology (Berl), 55, 49-52.
33. Klawans, H.L. & Rubovits, R. (1972) An experimental model of tardive dyskinesia. J. Neural. Transm., 33, 235-246.
34. + administration. Eur. J. Pharmacol., 175, 57-61.
35. Lau, Y.S. & Fung, Y.K. (1986) Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system. Brain Res., 369, 311-315.
36. Lerner, P., Nose, P., Gordon, E.K. & Lovenberg, W. (1977) Haloperidol: Effect of long-term treatment on rat striatal dopamine synthesis and turnover. Science, 197, 181-183.
37. Lohr, J.B. (1991) Oxygen radicals and neuropsychiatric illness. Some speculations. Arch. Gen. Psychiatry, 48, 1097-1106.
38. Meshul, C.K., Andreassen, O.A., Allen, C. & Jorgensen, H.A. (1996) Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology, 125, 238-247.
39. Meshul, C.K., Janowsky, A., Casey, D.E., Stalbaumer, R.K. & Taylor, B. (1992) Effect of haloperidol and clozapine on the density of 'perforated' synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology (Berl), 106, 45-52.
40. Meshul, C.K., Stallbaumer, R.K., Taylor, B. & Janowsky, A. (1994) Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res., 648, 181-195.
41. Narang, N. & Wamsley, J.K. (1995) Time dependent changes in DA uptake sites, D1 and D2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain. J. Chem. Neuroanat., 9, 41-53.
42. Nielsen, E.B. & Lyon, M. (1978) Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenithixol) in rats. Psychopharmacology (Berl), 59, 85-89.
43. Nomoto, M., Kaseda, S., Iwata, S., Shimizu, T., Fukuda, T. & Nakagawa, S. (2000) The metabolic rate and vulnerability of dopaminergic neurons, and adenosine dynamics in the cerebral cortex, nucleus accumbens, caudate nucleus, and putamen of the common marmoset. J. Neurol., 247, 16-22.
44. Pan, H.S., Penny, J.B. & Young, A.B. (1985) Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J. Neurochem., 45, 1396-1404.
45. Paxinos, G. & Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd Edn. Academic Press, New York.
46. Peacock, L. & Gerlach, J. (1997) A reanalysis of the dopamine theory of tardive dyskinesia the hypothesis of dopamine D1/D2 imbalance. In: Yassa R, Nair NPV, Jeste DV, (eds) Neuroleptic-Induced Movements Disorders., Cambridge University Press, New York, pp. 141-160.
47. Petzer, J.P., Bergh, J.J., Mienie, L.J., Castagnoli, N. Jr & Van der Schyf, C.J. (2000) Metabolic defects caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and by HPTP (the tetrahydropyridinyl analogue of haloperidol), in rats. Life Sci., 66, 1949-1954.
48. Rivest, R., Falardeau, P. & Di Paolo, T. (1995) Brain dopamine transporter: Gender differences and effect of chronic haloperidol. Brain Res., 692, 269- 272.
49. Sakai, K., Gao, X.M., Hashimoto, T. & Tammiga, C.A. (2001) Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse, 39, 2-16.
50. Sasaki, K., Kennedy, J.L. & Nobrega, J.N. (1997) Localized changes in GABA receptor-gated chloride channel in rat brain after long-term haloperidol: Relation to vacuous chewing movements. Synapse, 25, 73-79.
51. See, R.E. & Lynch, A.M. (1995) Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. Neuroreport, 6, 1795-1798.
52. Sherman, T.G. & Moody, C.A. (1995) Alterations in tyrosine hydroxylase expression following partial lesions of the nigrostriatal bundle. Mol. Brain Res., 29, 285-296.
53. Simantov, R., Blinder, E., Ratovitski, T., Tauber, M., Gabbay, M. & Porat, S. (1996) Dopamine-induced apoptosis in human neuronal cells: Inhibition by nucleic acids antisense to the dopamine transporter. Neuroscience, 74, 39-50.
54. Tamminga, C.A., Dale, J.M., Goodman, L., Kaneda, H. & Kaneda, N. (1990) Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains. Psychopharmacology (Berl), 102, 474-478.
55. Tarsy, D. & Baldessarini, R.J. (1974) Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology, 13, 927-940.
56. Tarsy, D. & Baldessarini, R.J. (1977) The pathophysiological basis of tardive dyskinesia. Biol. Psychiat., 12, 431-450.
57. Waddington, J.L. (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl), 101, 431-447.
58. Waddington, J.L. (1997) Rodent and other animals models of tardive dyskinesia during long-term neuroleptic drug administration. Controversies and Implications for the Clinical Syndrome. In Yassa R, Nair NPV, Jeste DV (eds) Neuroleptic-Induced Movements Disorder., Cambridge University Press, New York, pp. 225-237.
59. Waters, C.M., Peck, R., Rossor, M., Reynolds, G.P. & Hunt, S.P. (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in the Parkinson's disease and Huntington's chorea. Neuroscience, 25, 419-438.
60. Wright, A.M., Bempong, J., Kirby, M.L., Barlow, R.L. & Bloomquist, J.R. (1998) Effects of haloperidol metabolites on neurotransmitter uptake and release: Possible role in neurotoxicity and tardive dyskinesia. Brain Res., 788, 215-222.